Acurx Pharmaceuticals, Inc. (ACXP) is a publicly listed company that specializes in developing innovative therapies for infectious diseases. Founded with the primary goal of addressing the growing problem of antibiotic resistance, ACXP puts significant effort into creating new options for the medical community.
The company's focus rests primarily on developing therapies to treat bacterial infections, with multiple products currently in its pipeline. It aims to combat the global threat of antimicrobial resistance through the use of its proprietary technology platform, which has the potential to devise novel oral and IV antibiotics for infections caused by multi-drug resistant pathogens.
Headquartered in Connecticut, USA, Acurx Pharmaceuticals, Inc. leverages the extensive knowledge and experience of its team in this specialized field to create these novel antibiotics. The team is populated by industry veterans who have proven track records in pharmaceutical development, including the successful launch and commercialization of innovative medicines.
ACXP's lead product candidate, ibezapolstat, is currently under clinical development. This candidate, the first of a new class of antibiotics, is being developed as the first oral and IV antibiotic for Clostridioides difficile infection (CDI), one of the top three most urgent antibiotic-resistant bacterial pathogens, according to the CDC.
The company’s commitment to combatting antibiotic resistance is a notable and necessary endeavor in the current medical landscape. As more bacteria become resistant to existing antibiotics, the need for innovative new treatments becomes increasingly apparent. Acurx Pharmaceuticals, Inc. is therefore positioned to potentially play a pivotal role in the future of infectious disease treatment.
ACXP's vision to become a leader in this field is driven by a clear strategy that includes the in-licensing and development of innovative antimicrobial compounds. The company applies a streamlined clinical development process and is also open to strategic collaborations to accelerate the delivery of its therapies to patients in need.
Despite being a relatively young pharmaceutical company, Acurx Pharmaceuticals, Inc. has already made a commendable impact in the pharmaceutical industry. It continues to demonstrate its commitment to improving global health with its dedication to addressing the critical issue of antibiotic resistance. With its robust pipeline and strong investment in R&D, ACXP is expected to play a strategic role in the future of the pharmaceutical landscape.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Acurx Pharmaceuticals (ACXP) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. The Zacks rating system, which is based on changes in earnings outlook, suggests a positive impact on the stock price. This upgrade indicates an improvement in the company's underlying business and a strong potential for near-term stock price appreciation.
_07_03_2026_03_50_21_133108.jpg)
Acurx Pharmaceuticals (NASDAQ: ACXP) is registering up to 1,500,000 common shares for resale by Lincoln Park Capital Fund, LLC, which could generate up to $2.8 million in gross proceeds for Acurx from its own separate sales. These proceeds will be used for working capital, research and development, and general corporate expenses. Lincoln Park Capital Fund, LLC holds 409,789 shares prior to this offering and is authorized to resell up to 1.5 million shares, although Acurx will not receive funds from Lincoln Park's resale.
Acurx Pharmaceuticals announced that the FDA has conditionally accepted CIFBEZY as the brand name for its lead antibiotic candidate, ibezapolstat, and the USPTO has allowed the trademark application. These milestones are crucial as the company prepares to advance ibezapolstat into international Phase 3 clinical trials for treating and reducing the recurrence of C. difficile Infection (CDI). The company believes ibezapolstat could be a "game changer" by offering a single treatment for both acute CDI and recurrence prevention.
Acurx Pharmaceuticals reported a flat net loss of $2.254 million in Q2 2026, consistent with the prior year, despite higher R&D spending for its lead candidate ibezapolstat being offset by lower administrative expenses. The per-share loss narrowed significantly due to a substantial increase in share count following equity financing, which also boosted cash reserves. Key risks for the company include securing financing for international Phase 3 trials and its heavy reliance on a single late-stage asset.